View Larger Image

Development and Evaluation of RosetteArray Technology for Human Neurodevelopmental Toxicity Screening

Information about our National Institute of Environmental Health Sciences grant. Read more…

Amy Oler2022-09-27T11:33:44+00:00August 19, 2022|

Title

NEUROSETTA, LLC

4140A Wisconsin Institute for Discovery
330 N Orchard St
Madison, Wisconsin 53715
[email protected]

If publishing using a Neurosetta product or service, please cite Neurosetta, LLC, Madison WI.

Connect With Us!

MORE INFORMATION

© Neurosetta, LLC. All rights reserved.
This website was produced with support from the University of Wisconsin-System SBIR Advance Matching Grant Fund through its partnership with the Wisconsin Economic Development Corporation.

Development and Evaluation of RosetteArray Technology for Human Neurodevelopmental Toxicity Screening

New technology developed at UW-Madison aims to detect developmental disorders before birth

RosetteArray technology detects risk for Autism Spectrum Disorder

Neurosetta’s is the world-wide exclusive licensee of RosetteArray™ technology

Randolph Ashton (Co-founder & CEO of Neurosetta) Inducted into the 2023 Class of the AIMBE College of Fellows

Title

Development and Evaluation of RosetteArray Technology for Human Neurodevelopmental Toxicity Screening

Share This Story, Choose Your Platform!

Related Posts

New technology developed at UW-Madison aims to detect developmental disorders before birth

RosetteArray technology detects risk for Autism Spectrum Disorder

Neurosetta’s is the world-wide exclusive licensee of RosetteArray™ technology

Randolph Ashton (Co-founder & CEO of Neurosetta) Inducted into the 2023 Class of the AIMBE College of Fellows

Title

Click here to subscribe to our email list! Get the latest information about Neurosetta.